Introduciton
============

Rheumatoid arthritis (RA) afflicts up to 1% of the general population worldwide. It is a chronic inflammatory disease characterized by synovial hyperplasia and bone destruction in multiple joints (Firestein, [@B19]). Three of the outstanding questions in RA pathogenesis are how the systemic immune response is elicited by genetic and/or environmental factors, how this in turn results in local joint inflammation and how inflammation causes bone destruction. In the affected joints, hyperplasia of the synovial membrane is a hallmark of RA pathology, which is characterized by both hyperproliferation of synovial fibroblasts and massive infiltration of inflammatory immune cells, including CD4^+^T-cells and innate immune cells. Synovial fibroblasts have certain unique characteristics, such as hyperproliferative and hyperactive properties in response to an inflammatory environment, and are recognized as prominent determinants of the joint-specificity seen in RA. Therefore, it is important to establish how these pathogenetic immune cells migrate into joints and contribute to the chronic inflammation and bone destruction, especially via activation of the mesenchymal cells resident in joint, such as synovial fibroblasts. However, so far, despite the clearly evident importance and considerable effort expended, the interplay of immune and mesenchymal cells in joint is still not fully understood. Though significant roles of B-cells and antibody production are also widely appreciated in RA, here, we summarize recent findings on the RA pathogenesis by focusing on T-cells and synovial fibroblasts.

CD4^+^T-Cells are Indispensable for the Initiation of RA
========================================================

Although the etiology of RA remains unclear, the primary role of CD4^+^T-cells in RA has been suggested by various findings: (1) the extensive infiltration of CD4^+^T-cell into the inflammatory synovium, (2) the presence of autoantibodies, (3) the association of RA susceptibility with HLA-DRB1 alleles (Perricone et al., [@B72]) and genes related to T-cell function such as PTPN22 (Begovich et al., [@B8]; Lee et al., [@B51]) and CCR6 (Kochi et al., [@B44]; Stahl et al., [@B83]), and (4) the efficacy of a T-cell directed therapeutic drug, CTLA-4 Ig (Linsley and Nadler, [@B55]). Importantly, studies in a variety of animal models have further supported the importance of CD4^+^T-cells in RA development.

Collagen-induced arthritis (CIA) and K/BxN mouse (Kouskoff et al., [@B48]) model that recapitulate the whole process of RA are the most widely used mouse models. In these models, arthritogenic antibodies contribute to the development of RA, since transfer of arthritogenic antibodies can induce arthritis. CD4^+^T-cells are required for the full induction of CIA (Ranges et al., [@B75]) and K/BxN models (Kouskoff et al., [@B48]), as the administration of anti-CD4 depleting antibodies suppresses both the production of autoantibodies and disease severity (Table [1](#T1){ref-type="table"}). In contrast, CAIA (Kagari et al., [@B39]) and K/BxN serum transfer arthritis (Korganow et al., [@B46]) do not require T-cells or B-cells, since this form of arthritis can be induced effectively in T and B-cell-deficient mice. Thus, it is indicated that CD4^+^T-cells are required for the initiation phase of CIA and K/BxN arthritis partly by producing arthritogenic autoantibodies. CD4^+^T-cells are not strictly necessary after the production of arthritogenic autoantibodies, although this does not mean CD4^+^T-cells have no further role in the disease. Indeed, they are demonstrably capable of exacerbating arthritis, because adoptive transfer of a CD4^+^T-cell subset augments the severity in the CAIA (Nandakumar et al., [@B68]) and K/BxN serum transfer models (Jacobs et al., [@B36]).

###### 

**The contribution of proinflammatory cytokines and lymphocytes to the development of mouse models of RA**.

                         IL-17A   IL-6   IL-1   TNF   CD4^+^T-cell   B-cell
  ---------------------- -------- ------ ------ ----- -------------- --------
  CIA                    \+       \+     ++     \+    \+             \+
  SKG                    ++       ++     \+     \+    \+             −
  F759                   ++       ++     NR     NR    \+             −
  IL-1Ra-deficient       ++       −      NR     ++    \+             −
  CAIA                   NR       −      ++     ++    −              −
  K/BxN serum transfer   NR       −      ++     \+    −              −
  TNF-Tg                 NR       −      ++     ++    −              −

*−, Not required; +, partially required; ++, substantially required; NR, not reported*.

In this review, we divide a whole process of arthritis into the "initiation," "inflammatory," and "bone destruction" phases (Figure [1](#F1){ref-type="fig"}). We define the initiation phase as a phase when immune responses are triggered by an assumed antigen(s) and any apparent symptoms in joints are not yet observed. Inflammatory phase starts when any inflammatory symptoms such as swelling are recognized in joints and continues until any structural changes occur. Bone destruction phase is defined as a phase when structural damages in bone and cartilage are observed. Although the start point of initiation phase is difficult to tell in human, this phase must exist because it takes some time from the start to the point when clinical symptoms are observed. Thus, it is considered that both human RA and animal models of RA consist of all these phases.

![**Possible mechanisms of the initiation, inflammatory, and bone destruction phases in RA**. A variety of different cell populations, including lymphocytes, innate immune cells, synovial fibroblasts, and osteoclasts, play a role in the development of RA. Th17 cells contribute to the development of arthritis in each of the initiation, inflammatory, and bone destructive phases through the production of autoantibodies as well as the activation of innate immunity and synovial fibroblasts, and then ultimately, bone destruction. Importantly, synovial fibroblasts contribute to Th17 immunity in the inflammatory phase of arthritis by promoting the migration of Th17 cells into the inflammatory joint, and then homeostatic proliferation with an increase in IL-17 production. Thus, the interaction of CD4^+^T-cells and mesenchymal cells in joints plays a key role in the pathogenesis of RA in both the inflammation and bone destruction phases.](fimmu-03-00077-g001){#F1}

The significance of CD4^+^T-cells in RA development is also supported by T-cell-dependent models such as the SKG mouse, which has a mutation in ZAP70 (Sakaguchi et al., [@B77]), the F759 mouse with a mutation in the gp130 IL-6 receptor subunit (Atsumi et al., [@B6]), and the IL-1 receptor antagonist (IL-1Ra)-deficient mouse (Horai et al., [@B30]). These mice spontaneously develop arthritis due to a defect in TCR signaling or the altered sensitivity to inflammatory cytokines. The adoptive transfer of CD4^+^T-cells from SKG mice into SCID mice induces arthritis, indicating that the arthritis in SKG mice is CD4^+^T-cell-dependent (Sakaguchi et al., [@B77]). In addition, the arthritis which develops in F759 mice requires the presence of CD4^+^T-cells, but not CD8^+^T-cells or B-cells, in addition to the gp130 mutation in non-hematopoietic cells (Sawa et al., [@B79]). Furthermore, the arthritis in IL-1Ra-deficient mice is T-cell-dependent, as the T-cells from IL-1Ra-deficient mice induce disease in nude mice (Horai et al., [@B29]). Taken together, those T-cell-dependent mouse models indicate that RA can be provoked by CD4^+^T-cells without the need of B-cell help, due to an intrinsic defect in TCR signaling or altered sensitivity to proinflammatory cytokines (Table [1](#T1){ref-type="table"}).

In contrast, arthritis develops in human TNF-α transgenic (TNF-Tg) mice (Keffer et al., [@B41]) and mice with the myeloid-specific deletion of A20, a negative regulator of NF-κB signaling (Matmati et al., [@B59]). These arthritis are thought to recapitulate the inflammatory phase of RA, bypassing the initiation phase of RA. These mice develop arthritis even on the T, B-cell-deficient background (Douni et al., [@B18]). This suggested that hyperactivation of innate immune system is also able to induce RA (Table [1](#T1){ref-type="table"}).

Considering the necessity of CD4^+^T-cells for the initiation phase, one of the key questions is whether arthritogenic CD4^+^T-cells recognize a specific antigen, and if so, a joint-specific antigen or not. In the form of arthritis in K/BxN and CIA, arthritogenic CD4^+^T-cells recognize antigens that are abundant in the joints, although not exclusively joint-specific. In contrast, in the arthritis of F759 mice, the recognition of joint antigens by CD4^+^T-cells may not be required, because F759 mice expressing a single TCR variant that recognizes a non-joint antigen do indeed develop arthritis (Murakami et al., [@B64]). Moreover, the antigen specificity of arthritogenic CD4^+^T-cells in SKG mice remains unknown. Further studies are thus needed to elucidate the antigen specificity of arthritogenic CD4^+^T-cells, the finding of which will provide new insight into how immunological tolerance is broken by the generation of arthritogenic CD4^+^T-cells.

Taken together, CD4^+^T-cells are necessary for at least the initiation phase of arthritis partly by producing arthritogenic antibodies. In contrast, CD4^+^T-cells may not be required for the inflammatory phase of the disease, especially after arthritogenic autoantibodies are generated abundantly or innate immunity is hyper-activated. Nevertheless, CD4^+^T-cells have been shown to at least augment the inflammatory phase of arthritis development.

Th17 Cells: An Emerging Pathogenic Subset of CD4^+^T-Cells
==========================================================

The CD4^+^ helper T-cells (Th cells), that are differentiated from naïve CD4^+^T-cells include Th1, Th2, and Th17 cell subsets. Th17 cells, via their production of IL-17, promote the development of autoimmune diseases while also protecting host against bacterial and fungal infection. IL-6 and TGF-β induce Th17 development and IL-23 promotes Th17 cell expansion (Miossec et al., [@B62]). In the past, Th1 cells, which predominantly produce IFN-γ, were thought to be the principal T-cell player in the pathogenesis of RA. However, accumulating evidence from animal models in fact indicates that Th17 immunity is crucially important.

In CIA, accelerated RA development is evident in IFN-γ receptor-deficient mice (Manoury-Schwartz et al., [@B58]; Vermeire et al., [@B95]). In contrast, disease development is markedly diminished in mice with IL-17A deficiency (Nakae et al., [@B65]) or with antibody-mediated blockade of IL-17 (Lubberts et al., [@B56]). In the SKG model, RAG-deficient mice that received naïve SKG CD4^+^T-cells exhibited arthritis, along with concomitant Th17 generation. This arthritis is Th17-dependent, as RAG mice which received a transfer of IL-17-deficient T-cells did not exhibit any sign of arthritis (Hirota et al., [@B27]). Moreover, IL-1Ra-deficient mice with IL-17A deficiency display abrogated arthritis development (Nakae et al., [@B66]). Furthermore, F759 mice with IL-17A deficiency (Ogura et al., [@B70]) and K/BxN mice treated with a neutralizing IL-17A antibody exhibited substantially diminished arthritis (Wu et al., [@B99]). Taken together, as shown in Table [1](#T1){ref-type="table"}, regardless of whether the dependency was on IL-6, IL-1, or TNF-α, the development of arthritis was shown to be IL-17-dependent in most T-cell-dependent models, suggesting Th17 cell is a pathogenic subset of CD4^+^T-cells.

As for the function of IL-17, it augments the production of proinflammatory cytokines, chemokines, and matrix-degrading enzymes of various kinds of cells such as macrophages, dendritic cells (DCs), endothelial cells, and fibroblasts (Miossec et al., [@B62]). Thus, Th17 cells exacerbate the inflammatory phase of arthritis through the activation of various kinds of cells in the inflamed joints. In addition, IL-17 is responsible for the production of autoantibodies in CIA (Nakae et al., [@B65]) and K/BxN (Wu et al., [@B99]) mouse models. In particular, IL-17 has been shown to enhance germinal center (GC) formation in the K/BxN model. Thus, via IL-17 production, Th17 cells are able to exacerbate the initiation phase of arthritis through the production of autoantibodies. Moreover, IL-17 together with IL-6 amplifies the production of IL-6 by type 1 collagen^+^fibroblasts, which in turn enhances IL-17 production in T-cells (Ogura et al., [@B70]) as discussed below. Taken together, Th17 cells can exacerbate arthritis both in the initiation and inflammatory phases.

Cells other than Th17 cells are also reported to produce IL-17 in arthritis affected joints. In the synovium of CIA, γδT-cells also produce IL-17, although few IL-17^+^γδT-cells are in fact detected in the affected joints of SKG mice or RA patients (Ito et al., [@B35]). Mast cells also produce IL-17 in the inflamed joints of RA patients (Hueber et al., [@B32]). Although the functional relevance of other IL-17 producing cells remains to be clarified, considering the wealth of evidence for the significance of CD4^+^T-cells, it can be concluded that Th17 cells play a critical role in arthritis development.

Compared with the understanding of the function of Th17 cells, it remains largely unknown how Th17 cell are generated in the context of arthritis. Recently, several studies on this issue were reported. In SKG mice, Th17 cells are generated in the presence of the IL-6 produced by tissue-resident macrophages in response to C5a, because Th17 cell development is severely impaired in SKG mice having either a C5aR deficiency or a depletion of macrophages (Hashimoto et al., [@B26]). In addition, a deficiency of Toll-like receptor (TLR)-4 or administration of a TLR-4 antagonist suppresses the development of arthritis in IL-1Ra-deficient mice (Abdollahi-Roodsaz et al., [@B1]) and CIA (Abdollahi-Roodsaz et al., [@B2]) by decreasing the number of Th17 cells. This suggests that TLR-4 signaling is involved in Th17 generation. Moreover, in K/BxN mice, not only arthritis, but also Th17 generation and the production of arthritogenic autoantibodies cease under germ-free conditions, whereas the administration of even a single gut-residing species, segmented filamentous bacteria, can induce Th17 generation, GC formation, and the signs of arthritis. Thus, it is suggested that the gut environment affects the generation of IL-17^+^ cells, presumably including Th17 cells, leading to the onset of arthritis (Wu et al., [@B99]).

Given the significant role of Th17 cells in arthritis in mouse models, Th17 is now recognized as a promising therapeutic target. Thus, it is important to clarify the transcriptional mechanisms regulating Th17 development. ROR nuclear receptors are essential for Th17 development (Miossec et al., [@B62]). IkBζ also regulates Th17 development by cooperating with RORs (Okamoto et al., [@B71]). Antagonizing ROR activity has been shown to be effective in suppressing Th17 differentiation and Th17-mediated autoimmunity in mice using a synthetic ligand for RORs (Solt et al., [@B82]) as well as digoxin and its derivatives (Huh et al., [@B34]). In addition, Abs against IL-17A, LY2439821 (Genovese et al., [@B22]), and AIN457 (Hueber et al., [@B33]) have been shown to be beneficial for the treatment of RA in human, although they are unexpectedly less effective than anti-TNF Abs or anti-IL-6 Abs. This suggests that other IL-17 family members such as IL-17B or IL-17C may also contribute to RA pathogenesis (Yamaguchi et al., [@B101]). Alternatively, there may be a difference in the extent to which Th17 cells contribute to the pathogenesis of arthritis between mice and humans. Indeed, T-cells in the synovial fluid of patients with juvenile idiopathic arthritis (JIA) easily switch from a Th17 to Th1 phenotype via the intermediate step of a Th1/Th17 mixed phenotype (Cosmi et al., [@B16]), suggesting that human Th17 cells are more plastic than their mouse counterparts. In line with this, Ustekinumab, which is a human mAb against IL-12/23p40, significantly suppresses psoriatic arthritis in human (Gottlieb et al., [@B24]). In addition, a JAK inhibitor tofacitinib (CP690,550) which inhibits the established CIA presumably by suppressing pathogenic Th1 and Th17 cells (Ghoreschi et al., [@B23]), shows clinical benefit for RA (Kremer et al., [@B49]; Fleischmann et al., [@B20]). From this point of view, either an EP4 antagonist that blocks PGE2--EP4 signaling (Yao et al., [@B102]) or a depletion of anti-LT-α Abs (Chiang et al., [@B15]), which have been shown to suppress Th17-mediated autoimmune disease through the inhibition of both Th1 and Th17 immunity in mice, might be therapeutically beneficial in RA treatment.

Taken together, Th17 cells are crucial immune cells that are required for the initiation of arthritis and contribute to the augmentation of chronic inflammation in joints through the activation of both innate immunity and mesenchymal cells such as synovial fibroblasts in joints.

Innate Immune Cells: An Accelerator of Arthritis
================================================

In addition to T-cell infiltration, RA exhibits a massive infiltration into affected joints innate immune cells, including macrophages, neutrophils, mast cells, and DCs. These cells react to complement or the Fc portion of IgG isotypes via receptors expressed on their surface. They also produce proinflammatory cytokines, chemokines, and matrix-degrading enzymes that drive chronic inflammation.

The importance of innate immunity in arthritis development has been shown in both T-cell-dependent and independent mouse models. In the T-cell-dependent models, SKG mice fail to develop arthritis when they are raised under a specific pathogen free (SPF) condition, whereas SKG mice raised under a conventional environment do develop arthritis. In addition, SKG mice under an SPF condition develop severe arthritis when administrated zymosan, a crude yeast cell wall extract. Proinflammatory cytokines, presumably including TNF-α, which are produced by Dectin-1 expressing DCs or macrophages in response to zymosan, are involved in this process (Yoshitomi et al., [@B104]). In addition, macrophages produce IL-6 in response to C5a, leading to the generation of Th17 cells in SKG mice (Hashimoto et al., [@B26]). These findings indicate that activation of adaptive immunity requires innate immunity in the initiation phase of arthritis.

Among the T-cell-independent models, the K/BxN serum transfer model has helped address the mechanisms by which activation of innate immune system triggered by autoantibodies leads to the development of arthritis. In the K/BxN model, the autoantigen is the glucose-6-phosphate isomerase (GPI) that is expressed in the joint, although it is not joint-specific. GPI-anti-GPI immune complexes bind to articular surfaces, leading to the local augmentation of immune effecter responses in the joint (Matsumoto et al., [@B60]). K/BxN serum transfer arthritis requires complement C5 and FcγRIII (Ji et al., [@B37]). Neutrophils and mast cells are also required, as mice depleted of neutrophils (Wipke and Allen, [@B97]) and mice lacking mast cells (Lee et al., [@B52]) are both resistant to the arthritis.

As I mentioned above, TNF-Tg mice and mice with selective deletion of A20 (TNFAIP3) in myeloid cells do not require either T-cells or B-cells for the development of arthritis (Douni et al., [@B18]; Matmati et al., [@B59]). These studies suggest that hyperactivation of innate immunity is sufficient to induce arthritis. In addition, these findings prompt a consideration of how it is that a systemic gene mutation results in local joint inflammation. There may be certain joint-specific factors, possibly expressed by synovial fibroblasts, which drive the preferential migration of activated innate immune cells and thus the amplification of chronic inflammation in the affected joints.

Taken together, adaptive immunity requires the activity of innate immunity for the development of full blown arthritis both in the initiation and inflammatory phases. In addition, the hyperactivation of the innate immune response by itself is able to induce arthritis, presumably through an interaction with synovial fibroblasts, a unique mesenchymal cell population in joints.

Synovial Fibroblasts: Mesenchymal Cells that Determine Joint-Specificity
========================================================================

In general, all RA patients and RA model mice exhibit proliferative and erosive synovitis in regions adjacent to cartilage and bone, regardless of differences in the initiating mechanisms. Synoviocytes are divided into synovial fibroblasts of mesenchymal origin and macrophage-like synoviocytes, depending on their surface markers. RA synovial fibroblasts are key cells in the chronic inflammation which occurs in RA.

Synovial fibroblasts express not only receptors for proinflammatory cytokines, but also TLRs (Bartok and Firestein, [@B7]). In synovitis, synovial fibroblasts exhibit high proliferative activity and produce large amounts of cytokines, chemokines, and matrix-degrading enzymes in response to proinflammatory cytokines and TLR ligands, which lead to the exacerbation of synovitis and joint destruction. For instance, Tenascin-C, an extracellular matrix glycoprotein specifically expressed in inflamed joints, was shown to be an endogenous activator of the TLR-4 expressed by synovial fibroblasts and macrophages, and is also essential for maintaining synovitis in K/BxN serum transfer arthritis (Midwood et al., [@B61]). Interestingly, the microparticles produced by activated platelets amplify inflammatory arthritis in the K/BxN serum transfer model via a collagen-receptor expressed on synovial fibroblasts (Boilard et al., [@B10]).

The invasive characteristics of synovial fibroblasts from RA synovium have been reported in following studies. Cultured synovial fibroblasts from human RA synovium were shown to invade and destroy cartilage when co-transplanted with cartilage into SCID mice (Muller-Ladner et al., [@B63]). These transplanted RA synovial fibroblasts specifically migrate into a distal cartilage even in the absence of other immune cells (Lefèvre et al., [@B54]). Thus, it is suggested that synovial fibroblasts appear to have intrinsically invasive properties and to be destined to localize specifically in the joint. In addition, the invasive characteristics of synovial fibroblasts have also been reported in synoviocyte clones obtained from TNF-Tg mice (Aidinis et al., [@B3]). These results suggest that the intrinsically invasive properties of synovial fibroblasts from inflamed joints are stably maintained even after several passages in culture and that epigenetic modification may be involved in this process. Indeed, the DNA of RA synovial fibroblasts is hypomethylated both in synovial tissues and *in vitro* (Karouzakis et al., [@B40]). In addition, the ratio of histone acetylase/deacetylase activity is higher in RA synovial tissue than that in normal synovial tissue (Huber et al., [@B31]). Furthermore, synovial fibroblasts preferentially express microRNA 146a and 155, among microRNAs which function as posttranscriptional repressors of gene expression (Stanczyk et al., [@B84]). Further studies are needed to clarify the mechanisms of epigenetic modification and their role in the maintenance of the activated phenotype of synovial fibroblasts in arthritic joints.

Given that the infiltration of CD4^+^T-cells in inflamed joints is a hallmark of RA pathology, the interaction of synovial fibroblasts and CD4^+^T-cells is assumed to play an important role. By *in vitro* co-culture experiments, it has been demonstrated that RA synovial fibroblasts and CD4^+^T-cells activate each other through the ICAM-2 and LFA expressed on synovial fibroblasts and CD4^+^T-cells, respectively (Singh et al., [@B81]). In addition, the IL-15 expressed on RA synovial fibroblasts augments the production of effecter cytokines from CD4^+^CD25^−^ cells, while also enhancing the proliferation of CD4^+^CD25^+^Treg cells (Benito-Miguel et al., [@B9]). Several reports suggest an antigen-presenting role for synovial fibroblasts. RA synovial fibroblasts in tissue express MHC class (Burmester et al., [@B13]) IFN-γ treated synovial fibroblasts *in vitro* stimulate T-cell activation in an MHC class II dependent manner (Tran et al., [@B94]). However, the capacity for MHC class II restricted antigen presentation in synovial fibroblasts and its role in RA development *in vivo* remain to be demonstrated.

Importantly, several recent reports have shed light on the relevance of the interaction of CD4^+^T-cells and mesenchymal cells in the affected joint in the development of arthritis. In the SKG model, synovial fibroblasts produce CCL20 in response to proinflammatory cytokines such as TNF-α, leading to the recruitment of CCR6^+^Th17 cells into the affected joint. This recruitment is essential, as the administration of a neutralizing anti-CCR6 antibody ameliorates the development of arthritis (Hirota et al., [@B28]). Likewise, in F759 arthritis, type 1 collagen^+^fibroblasts produce CCL20 in response to local stimuli such as microbleeding and preferentially recruit CD4^+^T-cells into inflamed joints. The relevance of this recruitment has been demonstrated, because the inhibition of CCL20 diminished arthritis development (Murakami et al., [@B64]). In addition, non-hematopoietic cells, presumably synovial fibroblasts, produce elevated levels of IL-7 and IL-6, which enhances the homeostatic proliferation of CD4^+^T-cells and the production of IL-17 in Th17 cells, respectively (Sawa et al., [@B79]; Ogura et al., [@B70]). Moreover, IL-6 together with IL-17 amplifies IL-6 production of synovial fibroblasts (Ogura et al., [@B70]). In line with this, by *in vitro* co-culture system, a JAK inhibitor, Tofacitinib suppress the production of IL-6 by RA synovial fibroblasts through the inhibition of IL-17 and IFN-γ by RA CD4^+^T-cells (Maeshima et al., [@B57]).

Considering the important role of synovial fibroblasts, they may be a good therapeutic target for RA treatment. The induction of the cell senescence gene in synovial tissues successfully inhibits rat adjuvant-induced arthritis (Taniguchi et al., [@B91]). Yet only a few molecules have been identified as specific markers of synovial fibroblasts to date. Cadherin-11, a relatively specific marker, is required for the cellular connectivity of synovial fibroblasts. Cadherin-11-deficient mice exhibit a hypoplastic synovial lining of the synovium membrane and much less severe arthritis. Importantly, cadherin-11-directed therapeutics also markedly reduces synovial inflammation (Lee et al., [@B53]). Mechanistically, cadherin-11 contributes to the production of IL-6 in synovial fibroblasts (Chang et al., [@B14]). The identification of additional specific markers of synovial fibroblasts will ultimately lead to the establishment of "joint-preferential" therapeutic strategies.

These findings, taken together, indicate that synovial fibroblasts function as a unique "disease amplifier" in the inflammatory phase of RA through both the innate and acquired immunity pathways, due to their intrinsically invasive, hypersensitive, and hyperproliferative properties. Studies on animal models of RA have revealed the role of synovial fibroblasts in Th17 immunity, i.e., promoting the migration of Th17 cells to the affected joints and then homeostatic proliferation with an accompanying increase in IL-17 production, ultimately leading to the augmentation of the chronic inflammation which characterizes RA (Figure [1](#F1){ref-type="fig"}).

Proinflammatory Cytokines Mediate the Interplay between Immune Cells and Joints
===============================================================================

In RA synovium, elevated levels of the proinflammatory cytokines IL-1, IL-6, and TNF-α are produced by macrophages and synovial fibroblasts. These proinflammatory cytokines both directly and indirectly exert their effects through the production of additional proinflammatory cytokines and chemokines as well as matrix-degrading enzymes, resulting in a cytokine "storm" in the inflamed synovium. The relative contribution of IL-1, IL-6, and TNF-α to the development and progression of arthritis is different in the various mouse models (Table [1](#T1){ref-type="table"}).

In CIA, the blockade of IL-1 prevents arthritis (Joosten et al., [@B38]). IL-6 deficiency suppresses disease development (Alonzi et al., [@B4]). However, administration of a neutralizing anti-IL-6 mAb suppresses arthritis development when given early, but the suppressive effect is not observed when given in the later phases (Fujimoto et al., [@B21]). Likewise, the blockade of TNF-α markedly decreases inflammation and joint destruction when given early (Williams et al., [@B96]; Joosten et al., [@B38]). Recently, the growth factor progranulin was shown to bind to TNF receptors and block TNF-α/TNFR signaling. Progranulin reverses inflammatory arthritis in TNF-Tg mice and prevents the development of both CIA and CAIA (Tang et al., [@B90]). In addition, inhibition of migration of pathogenic T-cells into the joints and the prevention of emigration out of draining lymph nodes are observed in CIA mice in which TNF/TNFR signaling has been blocked (Notley et al., [@B69]). In line with this, impaired migration of T-cells into the joints is also observed in human RA patients treated with an anti-TNFα mAb (Taylor et al., [@B92]).

Overall, it is clear that there is a substantial difference in the relative contribution of these inflammatory cytokines to the development of arthritis (Table [1](#T1){ref-type="table"}). Dependency on IL-1 and TNFα in both the T-cell-dependent and independent arthritis models suggests that IL-1 and TNFα may be involved in the inflammatory phase of arthritis in mice. As for human RA, anti-TNF therapies achieved clinical remission while the IL-1 inhibitor IL-1Ra was less effective than would be expected from mouse studies, suggesting that IL-1 in RA may not be as important as it is in mouse arthritis (Buch et al., [@B12]). In contrast, the different pattern of dependency on IL-6 in the T-cell-dependent and T-cell-independent arthritis models suggests that IL-6 may be critically involved in T-cell mediated arthritis and affect pathogenesis of T-cells. Indeed, the protective effect of IL-6 blockade in CIA correlates with the inhibition of Th17 differentiation. In this model, IL-6 blockade was shown to be effective when administered at an early initiation phase (Fujimoto et al., [@B21]). However, a significant number of RA patients with the blockade of IL-6 signaling achieved clinical remission suggesting that IL-6 plays an important role even in the inflammatory phase in human.

Taken together, proinflammatory cytokines mediate the interplay between immune cells and joints, leading to the initiation and augmentation of chronic inflammation in RA. The substantial differences in cytokine-dependency in animal models may reflect the different effect of each cytokine in each phase of arthritis progression, in association with the triggering arthritogenic stimuli and type of the cells that constitute the inflammatory synovium.

Osteoclasts; A Key Player in the Bone Destruction Which Occurs in RA
====================================================================

In the pathology of RA, chronic inflammation leads to bone destruction. The synovium is a site where the immune system interferes with normal bone homeostasis. Bone homeostasis is maintained by a balance between the continuous resorption activity of osteoclasts and formation by osteoblasts. In RA, the bone destruction which takes place is mainly due to the excessive bone resorption activity of osteoclasts.

Osteoimmunology is a cross-disciplinary research field that investigates the interplay of the bone and immune system at the molecular level (Takayanagi, [@B85]). The interaction of osteoclasts and immune cells is a major topic of interest in this field. Studies of the relationship of osteoclasts and macrophages have led to important mechanistic insights into osteoclast differentiation. In addition, studies of the interaction of osteoclasts and T-cells have contributed to an improved understanding of the mechanism of bone destruction in RA.

Historically, increased numbers of osteoclast-like giant cells had been identified in the synovium of RA joints by the early 1980s (Bromley and Woolley, [@B11]). Based on these pathological findings, it was therefore suggested that osteoclasts have an important role in bone resorption in arthritis. Importantly, osteoclast formation from cultured synovial cells was successfully performed without the need of any other cells, demonstrating that rheumatoid synovial cells contain both osteoclast precursor cells and osteoclastogenesis-supporting cells (Takayanagi et al., [@B89]). However, the molecular mechanism still remained unclear until the identification of RANKL as an osteoclast differentiation factor expressed on synovial cells (Gravallese et al., [@B25]; Takayanagi et al., [@B86]).

Osteoclasts are formed when bone marrow cells are cultured in the presence of M-CSF and RANKL *in vitro*. Osteoclasts also are differentiated from bone marrow cells when co-cultured with mesenchymal cells, such as osteoblasts, in the presence of osteoclastogenic factors, including 1,25-dihydroxylvitamin D~3~, which induce RANKL expression on mesenchymal cells. Recent studies indicate that osteocytes, which are embedded in bone, express a higher amount of RANKL than osteoblasts and are thus the major source of RANKL in bone remodeling *in vivo* (Nakashima et al., [@B67]; Xiong et al., [@B100]).

RANKL is essential for osteoclast differentiation, as RANKL-deficient mice exhibit an osteopetrotic phenotype (Theill et al., [@B93]). Of note, a critical role for both RANKL and osteoclasts in arthritic bone destruction was demonstrated in mouse models of RA (Pettit et al., [@B73]; Redlich et al., [@B76]). Bone destruction did not occur in the absence of osteoclasts in either of these models, but a level of inflammation similar to that in their wild-type counterparts was observed, indicating that RANKL and osteoclasts are indispensable for bone destruction, but not for inflammation. There is a long-standing debate whether cells other than synovial fibroblasts express RANKL and thus contribute to osteoclastogenesis in arthritis. RANKL was originally identified as being expressed on activated T-cells (Wong et al., [@B98]). Histologically, in the RA synovium, RANKL is expressed by both synovial cells and T-cells (Kong et al., [@B45]; Gravallese et al., [@B25]; Takayanagi et al., [@B86]). In addition, RANKL expression on B-cells in the arthritic joints of RA patients was reported (Yeo et al., [@B103]). However, it still remains unclear the extent to which lymphocytes, as a source of RANKL, contribute to the bone destruction in arthritis. Mice bearing a cell type-specific deletion of RANKL will be required to decide this issue. Given the important role of RANKL in osteoclastogenesis, RANKL is a promising pharmacological target for the prevention of joint destruction. Indeed, an anti-RANKL antibody was recently shown to inhibit joint destruction in human RA patients (Dore et al., [@B17]).

The discovery of RANKL shed light on the importance of understanding the molecular mechanisms that underlie osteoclast differentiation and function, which has led to the identification of NFATc1 as a master transcription regulator of osteoclastogenesis (Takayanagi et al., [@B88]) and other related signaling molecules. Notably, tyrosine kinases Btk and Tec regulate osteoclastogenesis and the inhibition of Tec kinase reduce inflammation-induced bone destruction (Shinohara et al., [@B80]). Further studies regarding precise mechanisms of osteoclast differentiation and function are required for a precise molecular basis for novel therapeutic strategies.

Synovial Fibroblasts Promote Osteoclastogenesis via Interaction with Immune Cells
=================================================================================

Activated T-cells express not only RANKL but also effector cytokines, including cytokines with either stimulatory or inhibitory effects on osteoclastogenesis, as shown in Table [2](#T2){ref-type="table"} (Takayanagi et al., [@B87]; Takayanagi, [@B85]). Thus, the osteoclastogenic capacity of T-cells is determined by both RANKL and cytokine expression.

###### 

**T-cell-related cytokines and osteoclastogenesis**.

  Th cell subsets   Associated cytokines   Main producer cells                         Effects on osteoclastogenesis
  ----------------- ---------------------- ------------------------------------------- -------------------------------
  Th1 cells         IFN-γ                  Th1 cells and NK cells                      Inhibition
                    GM-CSF                 Th1 cells                                   Inhibition
                    IL-12                  Macrophages and DCs                         Inhibition
  Th2 cells         IL-4                   Th2 cells and Mast cells                    Inhibition
                    IL-10                  Th2 cells and Treg cells                    Inhibition
  Th17 cells        IL-17                  Th17 cells, γδT-cells, and Mast cells       Activation
                    RANKL                  Synoviocytes, Osteoblasts, and Th17 cells   Activation
                    IL-1                   Macrophages, Synoviocytes, and Mast cells   Activation
                    IL-6                   Macrophages, DCs, and Synoviocytes          Activation
                    IL-21                  Th17 cells, NKT cells                       Activation
                    IL-22                  Th17 cells, NK cells                        Activation
                    IL-23                  DCs and Macrophages                         Activation
                    TNFα                   Macrophages and DCs                         Activation
  Treg cells        IL-10                  Th2 cells and Treg cells                    Inhibition
                    TGF-β                  Treg cells and DCs                          Activation

*The associated cytokines include those produced by T-cells as well as those that are important for T-cell induction*.

IL-17 is known to enhance osteoclastogenesis *in vitro* by acting on osteoclastogenesis-supporting cells (Kotake et al., [@B47]). Of note, Th17 cells, but neither Th1 cell nor Th2 cells, comprise the osteoclastogenic helper T subset. Th17 cells do not produce either IFN-γ or IL-4, each of which inhibits osteoclastogenesis, but do produce IL-17, which stimulates osteoclastogenesis by its effect on osteoblasts that act as osteoclastogenesis-supporting mesenchymal cells (Sato et al., [@B78]).

Therefore, the presumable roles of IL-17 in the bone destruction which occurs in RA are as follows. First, IL-17 exerts its osteoclastogenic effect by stimulating RANKL expression by synovial fibroblasts. Furthermore, IL-17 up-regulates the expression of proinflammatory cytokines such as IL-1, IL-6, and TNF-α, which promote osteoclastogenesis through their effects on osteoclast precursor cells by enhancing RANK mediated signaling, or indirectly through upregulation of RANKL expression by synovial fibroblasts. These events synergistically promote osteoclastic bone resorption in the inflamed synovium.

Besides IL-17, IL-21(Kwok et al., [@B50]), and IL-22 (Kim et al., [@B42]), which are also produced by Th17 cells, stimulate osteoclastogenesis mainly by upregulating RANKL expression in synovial fibroblasts. Thus, it is plausible that synovial fibroblasts augment their capacity to induce osteoclastogenesis in the presence of Th17 cells.

An important role for Th17 in bone destruction is supported by studies in mouse models. In CIA, the neutralization of IL-17 after the onset of arthritis reduces the severity of joint destruction (Lubberts et al., [@B56]). Although both Th17 cells and γδT-cells produce IL-17 in the affected joints of CIA, Th17 cells, but not γδT-cells, have been shown by antibody-mediated depletion and adoptive transfer studies to reside adjacent to osteoclasts and to play a prominent role in bone destruction *in vivo* (Pollinger et al., [@B74]).

Osteoclast precursor cells express receptors for proinflammatory cytokines. Most of the proinflammatory cytokines which augment inflammation also promote osteoclastogenesis by augmenting RANK--RANKL signaling, with the exception that TNF-α and TGF-β together induce osteoclastogenesis even in the absence of RANK (Kim et al., [@B43]) This suggests that the inhibition of proinflammatory cytokines by neutralizing Abs would play a dual role in the suppression of inflammation and bone destruction in RA. Interestingly, the inhibition of cathepsin K, which was thought to be expressed exclusively by osteoclasts and to play an essential role in bone degradation, has been shown to play dual role in suppression of osteoclastic bone resorption and TLR-9 mediated-activation of DCs (Asagiri et al., [@B5]).

Taken together, synovial fibroblasts contribute not only to chronic inflammation but also to the bone destruction which occurs in RA by promoting RANKL-mediated osteoclastogenesis through the interaction of immune cells, mainly Th17 cells.

Concluding Remarks
==================

Rheumatoid arthritis is an immune-mediated disease, characterized by local inflammation and bone destruction in joint as a result of alteration of systemic immune response. Recent studies have revealed that Th17 cells and synovial fibroblasts are the critical regulators. As shown in Figure [1](#F1){ref-type="fig"}, Th17 cells, differentiated in the presence of innate immunity, help B-cells produce arthritogenic autoantibodies in the initiation phase. In inflamed joints, Th17 cells activate innate immune cells and synovial fibroblasts by upregulating proinflammatory cytokines and matrix-degrading enzymes, thereby leading to an amplification of chronic inflammation. Moreover, Th17-related cytokines stimulate the differentiation of osteoclasts, mainly via the synovial fibroblasts in the joints, which eventually leads to bone destruction. Thus, Th17 cells are not only required for the initiation of the systemic immune response, they contribute to chronic inflammation and bone destruction. Importantly, synovial fibroblasts contribute to Th17 immunity in both the inflammatory and bone destruction phases of arthritis by promoting the migration of Th17 cells into the joint, inducing homeostatic proliferation with a concomitant increase in IL-17 production and promoting osteoclastogenesis by upregulation of RANKL expression. It is thus suggested that synovial fibroblasts connect the systemic immune response to local joint disorders by their intrinsic characteristics, including their "hyper-reactivity" and "hyper-chemoattractivity" in response to inflammatory stimuli.

Collectively, the interaction of immune cells and non-hematopoietic mesenchymal cells in the joints plays a key role in the pathogenesis of RA in both the inflammatory and bone destruction phases. Elucidation of the precise mechanisms involved in this interaction will lead to a better understanding of RA and provide a molecular basis for effective therapeutic strategies against this disease. Furthermore, the findings obtained from such investigation of RA will undoubtedly prove applicable to other diseases evoked through the interaction of immune and mesenchymal cells.
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